sinc
begin
centuri
scientist
tri
stimul
antitumour
activ
immun
system
fight
cancer
howev
scientif
effort
devot
develop
cancer
immunotherapi
translat
expect
clinic
success
contrari
classic
antineoplast
treatment
surgeri
radiotherapi
chemotherapi
first
line
treatment
nevertheless
compel
evid
immunogen
cancer
cell
capac
immun
system
expand
cancerspecif
effector
cytotox
cell
howev
effect
activ
anticanc
cell
respons
strongli
depend
effici
tumour
antigen
present
profession
antigen
present
cell
dendrit
cell
dc
sever
strategi
use
boost
dc
antigen
present
function
end
cancer
immunotherapi
effect
would
expect
accord
preclin
model
review
comment
discrep
focus
attent
contribut
regulatori
cell
myeloidderiv
suppressor
cell
lack
therapeut
success
dcbase
cancer
immunotherapi
long
ago
convers
colleagu
mine
differ
research
interest
ask
much
interest
cancer
research
keen
infecti
diseas
particular
question
made
think
motiv
work
cancer
research
cancer
mani
case
adult
noncontagi
diseas
except
infecti
diseas
attack
anyon
time
addit
infecti
agent
highli
contagi
new
one
aris
time
time
argu
compar
cancer
infecti
diseas
much
higher
health
burden
worldwid
convers
quickli
look
statist
accord
cancer
research
uk
http
wwwcancerresearchukorg
million
death
cancer
look
death
caus
infecti
diseas
accord
world
health
organis
http
wwwwhointen
million
death
age
caus
infecti
diseas
even
though
data
recent
conclud
first
premis
health
burden
might
complet
accur
howev
ultim
reason
look
therefor
cancer
fascin
attract
much
scientif
medic
effort
among
nonmed
commun
develop
world
infecti
diseas
problem
histor
use
apart
except
aid
owe
introduct
hygien
measur
sanit
possibl
signific
factor
vaccin
control
everyday
infect
nevertheless
doubt
medic
commun
mass
vaccin
effect
way
achiev
popul
immun
essenti
erad
infecti
agent
worthi
mention
overal
popul
case
forgotten
import
mass
vaccin
common
infecti
agent
wellknown
phenomenon
denomin
vaccin
refus
seriou
consequ
delay
erad
infecti
diseas
recent
exampl
import
measl
viru
outbreak
england
outbreak
new
journal
scienc
seriou
consequ
proport
infect
children
caus
vaccin
refus
tripl
measlesmumpsrubella
vaccin
due
fear
unfound
link
autism
therefor
goodintent
nonrat
decis
made
follow
inaccur
percept
real
signific
impact
popul
health
statu
propag
infecti
diseas
howev
cancer
differ
matter
doubt
mind
anyon
would
vaccin
children
cancer
well
one
hand
longer
live
higher
chanc
suffer
type
cancer
secondli
cancer
quickli
kill
patient
without
much
modern
medicin
prevent
thirdli
radiotherapi
chemotherapi
caus
sever
secondari
effect
mani
case
prolong
life
cure
cancer
point
view
popul
howev
fascin
scientist
well
answer
lie
scientif
challeng
cancer
aris
complic
caus
uncontrol
growth
transform
cell
tumour
would
problem
tumour
remov
surgeri
howev
left
untreat
cell
eventu
colonis
organ
process
call
metastasi
establish
secondari
tumour
cancer
cell
coloni
significantli
interfer
physiolog
function
organ
challeng
lie
cell
come
selftissu
therefor
immun
system
larg
toler
case
infecti
diseas
viral
bacteri
product
foreign
nonself
rel
easi
immun
cell
detect
get
rid
infecti
agent
develop
vaccin
infecti
diseas
rel
straightforward
comparison
cancer
vaccin
case
cancer
alert
immun
system
mutat
selfcel
realli
play
role
control
cancer
begin
centuri
paul
ehrlich
put
forward
tumour
immunosurveil
theori
alreadi
work
role
immun
respons
control
infect
caus
microorgan
appli
observ
cancer
propos
cancer
cell
spontan
aris
organ
immun
respons
could
effect
elimin
concept
later
refin
burnet
fast
develop
organ
chemistri
biochemistri
molecular
biolog
nuclear
physic
follow
centuri
provid
tool
systemat
studi
cancer
develop
chemotherapeut
agent
could
inhibit
cancer
cell
growth
first
time
drug
could
develop
effect
least
control
case
cure
combin
surgeri
radiotherapi
cancer
therefor
biomed
research
direct
effort
develop
new
drug
studi
anticanc
immun
respons
steadili
continu
never
reach
therapeut
statu
achiev
convent
method
lack
success
cancer
vaccin
led
anoth
misconcept
still
linger
within
rel
larg
proport
scientif
commun
immun
respons
play
signific
role
control
cancer
unlik
classic
antineoplast
strategi
radiotherapi
chemotherapi
interestingli
strong
recent
evid
classic
anticanc
treatment
heavili
reli
immun
system
effect
treatment
includ
radiotherapi
chemotherapi
depend
cellular
stress
respons
respons
lead
enhanc
antitumour
activ
activ
tlr
agonist
releas
necrot
tumour
cell
activ
inflammasom
antigen
present
cell
releas
atp
interestingli
convent
antineoplast
treatment
lose
efficaci
immunocompromis
mice
use
experi
human
patient
deleteri
mutat
determin
whether
cancer
vaccin
becom
success
human
immunotherapi
exactli
requir
infecti
diseas
cancer
immunogen
activ
cytotox
cell
respons
consequ
cancer
cell
possess
immunogen
antigen
suscept
target
vaccin
sinc
ehrlich
propos
research
look
tumourassoci
antigen
taa
could
exploit
cancer
immunotherapi
even
though
earli
studi
found
experiment
evid
toward
exist
particularli
virusinduc
tumour
problem
immunolog
toler
alway
came
back
counterattack
mani
studi
concentr
immun
respons
virusinduc
tumour
rather
endogen
cancer
antigen
fact
time
increasingli
accumul
bodi
evid
support
viral
aetiolog
nearli
human
cancer
result
major
slightli
misguid
chang
view
cancer
therapi
much
easier
target
foreign
viral
antigen
express
tumour
cell
mutat
selfantigen
know
number
human
cancer
caus
viral
infect
nevertheless
viral
aetiolog
theori
human
cancer
could
explain
immun
respons
chemic
induc
cancer
also
observ
howev
mani
instanc
result
could
reproduc
research
group
even
earli
studi
provid
evid
immun
respons
could
rais
tumour
nonvir
origin
spontan
tumour
regress
also
sporad
observ
human
patient
case
provok
immunis
toward
common
pathogen
strongli
support
exist
taa
nonvir
origin
turn
point
came
studi
oncogen
virus
especi
retrovirida
famili
led
shock
discoveri
virus
induc
cancer
express
oncogen
correspond
cellular
variant
oncogen
includ
vraf
cmi
crel
kra
among
other
protein
larg
involv
regul
cell
prolifer
surviv
transform
oncovirus
hijack
cellular
oncogen
advantag
cancer
nonvir
aetiolog
correspond
cellular
version
involv
carcinogenesi
turn
case
cancer
cell
accumul
seri
mutat
lead
genet
instabl
result
protein
express
chang
increas
surviv
uncontrol
prolifer
mani
mutat
protein
transcript
factor
cmyc
part
key
signal
pathway
human
ra
cell
cycl
regul
retinoblastoma
protein
rb
antioncogen
result
uncontrol
prolifer
defect
dna
repairapoptosi
pathway
mutat
chromosom
rearrang
appear
fortun
direct
consequ
cell
express
collect
mutat
selfprotein
confer
degre
immunogen
quasiantigen
case
selfprotein
aberrantli
overexpress
tumour
would
normal
express
correspond
healthi
tissu
acquir
immunogen
allow
immun
system
identifi
destroy
evid
exist
immunogen
autolog
tumour
antigen
appear
year
ago
sinc
increasingli
grow
collect
taa
identifi
intent
review
provid
extens
detail
list
taa
identifi
far
howev
worthi
mention
wide
use
human
therapi
discov
tyrosinas
overexpress
melanoma
alreadi
observ
tyrosinas
oxidas
involv
melanin
product
specif
express
melanocyt
interestingli
shown
immunogen
tyrosinasespecif
cell
could
lyse
melanoma
cell
line
cell
demonstr
recognis
hladrspecif
tyrosinas
peptid
epitop
tyrosinasederiv
peptid
use
vaccin
melanoma
alon
combin
taa
carcinoembryon
antigen
cea
indirectli
identifi
detect
anticea
antibodi
human
colon
cancer
patient
cea
cell
adhes
glycoprotein
immunoglobulin
superfamili
express
foetal
develop
interestingli
cea
reexpress
especi
colorect
cancer
although
also
express
mani
carcinoma
express
pattern
made
good
candid
immunotherapi
ceaspecif
cell
respons
demonstr
ceaderiv
immunogen
cell
peptid
identifi
sever
differ
peptid
epitop
found
use
human
immunotherapi
licens
ceabas
vaccin
extens
use
mani
variat
cancer
immunotherapi
strong
evid
support
role
anticea
cell
respons
break
immunolog
toler
toward
tumour
antigen
alphafetoprotein
afp
report
express
tumour
afp
globulinlik
plasma
protein
present
high
level
foetal
develop
elev
particularli
hepat
cancer
afp
current
use
tumour
marker
rather
immunotherapi
target
strongli
inhibit
cell
respons
nevertheless
immunogen
cell
epitop
also
identifi
could
use
target
cancer
vaccin
alon
combin
taa
cancer
antigen
highli
express
ovarian
carcinoma
discov
specif
reactiv
murin
monoclon
antibodi
toward
ovarian
carcinoma
cell
line
glycoprotein
belong
mucin
famili
gener
immunosuppress
correl
tumour
progress
evid
immun
respons
rais
could
therapeut
relev
elev
prostatespecif
antigen
psa
observ
prostat
hyperplasia
cancer
psa
peptidas
express
epitheli
cell
prostat
gland
classic
use
tumour
maker
although
reliabl
question
psa
also
use
cancer
immunotherapi
prostat
cancer
vaccin
immunogen
cell
epitop
also
describ
melanomaassoci
antigen
mage
antigen
cancertesti
antigen
also
express
wide
varieti
cancer
describ
earli
shown
contain
mani
immunogen
cell
peptid
epitop
mage
antigen
also
big
player
develop
cancer
vaccin
success
appli
human
immunotherapi
protocol
lead
melanoma
regress
use
also
break
toler
toward
taa
also
immunogen
tyrosinaserel
protein
clone
frequent
overexpress
melanoma
cell
epitop
also
identifi
taa
especi
highli
immunogen
protein
taa
interest
human
therapi
although
one
immunogen
melanomaassoci
antigen
interestingli
use
select
mutat
cell
epitop
effect
break
immunolog
toler
drive
effect
antimelanoma
respons
immun
respons
also
lead
melanoma
regress
protein
identifi
reactiv
melanocyt
lineagespecif
monoclon
antibodi
use
diagnosi
human
melanoma
later
clone
demonstr
human
cytotox
cell
could
recognis
immunogen
epitop
particular
taa
extens
use
develop
melanoma
vaccin
cancertesti
antigen
isol
esophag
squamou
cell
carcinoma
immun
respons
demonstr
human
also
express
wide
rang
cancer
includ
ovarian
cancer
melanoma
sarcoma
neuroblastoma
leukaemia
lymphoma
name
sever
cell
epitop
defin
relev
trigger
anticanc
immun
respons
possibl
one
best
antigen
human
immunotherapi
due
wide
express
pattern
immunogen
cell
modifi
express
tcr
shown
induc
tumour
regress
metastat
synovi
cell
sarcoma
melanoma
clone
melanoma
cell
linederiv
cdna
librari
transfect
target
cell
lysi
establish
melanomaspecif
cytotox
cell
tcr
identifi
human
patient
shortli
shown
specif
peptid
epitop
extens
use
togeth
taa
vaccin
melanoma
fact
evid
suggest
activ
cell
promin
effect
immunotherapi
melanoma
genet
engin
autolog
cell
express
tcr
demonstr
capac
achiev
melanoma
regress
longterm
cure
anim
model
human
patient
summaris
cancer
cell
fact
immunogen
immunolog
silent
wide
rang
common
taa
express
rang
cancer
rais
cell
fact
numer
studi
preclin
experiment
model
human
clinic
trial
report
effect
cell
respons
howev
overal
clinic
success
cancer
immunotherapi
rather
low
even
though
taaspecif
autolog
cell
expand
fact
cell
exert
good
cytotox
activ
ex
vivo
mediat
strong
tumour
regress
vivo
end
longterm
cure
infrequ
tumour
usual
come
back
escap
immun
system
use
varieti
mechan
mechan
involv
select
cancer
cell
variant
lose
taa
express
decreas
express
mhc
molecul
review
involv
regulatori
immun
cell
expand
cancer
strongli
inhibit
anticanc
immun
respons
discuss
discuss
cancer
cell
express
mani
taa
case
appear
wide
rang
cancer
rel
high
frequenc
howev
presenc
potenti
immunogen
taa
directli
answer
question
whether
immun
system
play
central
role
control
cancer
physiolog
condit
word
whether
immun
system
compet
protect
organ
cancer
absenc
extern
intervent
immun
system
would
fact
compet
strategi
boost
natur
antineoplast
activ
could
succeed
human
therapi
prove
whether
cancer
immunosurveil
hypothesi
basi
compel
evid
role
immun
system
keep
potenti
cancer
cell
bay
aris
organ
came
observ
cancer
immunoedit
sever
research
group
notic
cancer
grow
immunodefici
mice
far
immunogen
cancer
grown
immunocompet
mice
cell
respons
rais
tumour
regress
appar
cancer
cell
escap
immun
system
escape
lost
immunogen
demonstr
immun
system
exert
time
select
pressur
absenc
immun
respons
tumour
immunogen
presenc
compet
immun
respons
less
immunogen
tumour
select
immun
pressur
nowaday
fourstag
process
oncogenesi
wide
recognis
tumour
immunologist
transform
cancer
cell
rais
anticanc
immun
respons
establish
cancer
growthimmun
attack
equilibrium
exert
select
pressur
immunolog
escap
poorli
immunogen
cancer
cell
succeed
cancer
necessari
strongli
boost
step
reduc
maximum
establish
cancerimmun
system
equilibrium
natur
anticanc
immun
respons
clearli
amplif
taaspecif
effector
cell
howev
amplif
much
smaller
found
cell
respons
infecti
agent
taaspecif
cell
usual
low
affin
even
anerg
antitumour
attack
limit
number
effector
cell
shift
equilibrium
balanc
toward
select
escap
cancer
cell
effect
anticanc
therapi
amplif
larg
number
effector
cell
necessari
culmin
blitz
attack
leav
chanc
immun
escap
figur
antitumour
cell
respons
need
reach
critic
mass
effect
recent
propos
mechan
base
experiment
observ
critic
mass
hypothesi
cell
respons
figur
therefor
main
object
cancer
immunotherapi
strongli
stimul
immun
system
varieti
procedur
boost
natur
antitumour
immun
implement
novel
antitumour
properti
immun
cell
exampl
genet
modif
cancer
immunotherapi
group
varieti
techniqu
direct
increas
activ
b
dendrit
cell
dc
rais
strong
antitumour
immun
respons
manipul
cell
type
carri
convent
techniqu
use
vaccin
adjuv
togeth
taa
cytokinechemokin
therapi
moleculargenet
techniqu
success
exampl
procedur
express
cell
taaspecif
cell
receptor
tcr
chimer
antigen
receptor
car
direct
toward
tumour
antigen
administr
taaload
dc
nevertheless
success
cancer
immunotherapi
imper
achiev
strong
effect
taa
present
effector
cytotox
cell
especi
cell
cancer
immunotherapi
depend
enhanc
potent
cytotox
cell
ctl
respons
taa
antigen
process
seri
antigen
peptid
load
mhc
peptidemhc
complex
expos
surfac
antigen
present
cell
apc
also
normal
transform
cell
antigen
present
apc
lead
activ
effector
new
journal
scienc
figur
critic
mass
taaspecif
cytotox
cell
necessari
reduc
immunolog
edit
cancer
escap
tumour
mass
repres
group
transform
cell
orang
attack
limit
number
taaspecif
cell
left
immunolog
edit
take
place
indic
arrow
due
limit
slow
kill
taaexpress
cell
leav
signific
number
poorli
immunogen
cancer
cell
aliv
centr
cell
eventu
regrow
reduc
immunogen
lack
cell
attack
right
b
situat
differ
larg
pool
taaspecif
cytotox
cell
expand
follow
immunotherapi
left
way
larger
number
cancer
cell
kill
tumour
mass
leav
cell
reduc
number
aliv
situat
minimis
immunolog
edit
cancer
escap
centr
end
turn
mani
cancer
immunotherapi
treatment
tumour
usual
come
back
howev
comparison
situat
shown
take
longer
tumour
regrow
associ
increas
surviv
cell
present
surfac
normal
cell
discrimin
normal
healthi
cell
infect
transform
cell
briefli
antigenspecif
cell
expand
apc
look
cell
expos
correspond
antigen
peptidemhc
complex
found
cell
exert
cytotox
activ
elimin
infectedtransform
cell
cell
recognis
cognat
antigen
peptid
activ
direct
bind
tcr
peptidemhc
complex
present
surfac
apc
figur
recognit
deliv
signal
lymphocyt
insuffici
effect
activ
antigenpres
apc
provid
addit
signal
immunolog
synaps
cell
cosign
regul
degre
cell
activ
stimulatori
inhibitori
major
costimulatori
interact
take
place
bind
apc
cell
howev
array
inhibitori
interact
also
occur
immunolog
synaps
bind
integr
posit
neg
costimul
determin
degre
cell
activ
figur
addit
two
signal
specif
cytokin
profil
produc
dct
cell
engag
drive
cell
differenti
toward
helper
th
subtyp
differ
respons
proinflammatori
driven
antibodi
respons
control
immun
suppress
regul
regulatori
cell
differenti
respons
infecti
agent
usual
strong
specif
reli
upon
recognit
pathogenderiv
molecul
apc
dc
case
anticanc
respons
activ
taaspecif
cell
certainli
challeng
firstli
taa
express
low
concentr
lead
suboptim
antigen
present
situat
cell
recognis
antigenpres
cell
minut
concentr
differenti
toward
treg
hand
well
known
cell
effici
activ
engag
low
number
peptidemhc
complex
process
call
serial
tcr
trigger
taken
account
pmhc
complex
bind
tcr
low
affin
anyway
costimul
play
part
strengthen
tcrpmhc
bind
howev
tcr
manipul
genet
engin
increas
signal
lead
effect
cancer
immunotherapi
anim
model
human
clinic
trial
engag
dc
pathogenderiv
molecul
caus
dc
matur
upregul
costimulatori
signal
mhc
molecul
secret
pathogenspecif
cytokin
profil
matur
dc
migrat
secondari
lymphoid
tissu
present
pathogenderiv
antigen
specif
cell
howev
case
cancer
taa
frequent
aberrantli
overexpress
endogen
protein
quasiantigen
major
problem
anticanc
immun
respons
frequenc
taaspecif
cell
gener
low
remov
clonal
delet
thymu
circul
autoreact
cell
escap
clonal
delet
possess
lowaffin
tcr
alreadi
differenti
natur
treg
thymu
alreadi
discuss
throughout
review
mani
immunotherapeut
approach
treatment
cancer
briefli
focu
use
dc
cancer
immunotherapi
sinc
signific
research
effort
dedic
therapeut
target
dc
steinman
cohn
discov
convent
dc
cell
found
potent
activ
cell
respons
also
strong
inhibitor
appropri
activ
dendrit
cell
compris
heterogen
group
cell
type
deriv
haematopoiet
precursor
frequent
classifi
two
broad
group
accord
lineag
myeloid
convent
dc
plasmacytoid
dc
major
breakthrough
occur
twenti
year
ago
convent
dc
shown
effici
differenti
ex
vivo
mous
bone
marrow
use
gmcsf
four
year
later
correspond
dc
product
method
human
monocyt
publish
use
combin
gmcsf
possibl
ex
vivo
expans
significantli
stimul
dcbase
immunotherapi
due
high
reproduc
procedur
eas
use
addit
previou
specif
knowledg
particular
antigen
peptid
epitop
given
antigen
requir
dc
could
effici
take
antigen
process
antigen
present
figur
even
specif
hla
genotyp
patient
autolog
dc
could
differenti
load
ex
vivo
antigen
reintroduc
patient
addit
dc
number
limit
factor
around
million
dc
reproduc
obtain
singl
mous
bone
marrow
one
week
pbmc
larg
number
dc
still
obtain
although
human
therapi
procedur
slightli
cumbersom
blood
taken
high
quantiti
patient
cultur
dc
immatur
ensur
modifi
matur
use
requir
stimuli
immunotherapi
effici
cell
yield
allow
systemat
characteris
wide
varieti
immunostimulatoryinhibitori
treatment
figur
one
key
problem
cancer
immunotherapi
effect
activ
taaspecif
effector
cell
dc
vaccin
might
one
best
immunotherapeut
strategi
enhanc
potent
antigenpres
strategi
might
suffici
strongli
activ
lowaffin
effector
cell
break
natur
toler
toward
endogen
taa
dc
present
surfac
wide
collect
receptor
recognis
varieti
pathogenassoci
molecular
pattern
inflammationrel
cellular
protein
bind
molecul
appropri
receptor
trigger
phenotyp
function
matur
strong
upregul
mhc
costimulatori
molecul
antigen
present
figur
abil
grow
ex
vivo
larg
quantiti
dc
allow
detail
studi
cellular
molecular
mechan
antigen
present
cell
procedur
end
dc
present
antigen
peptid
surfac
associ
mhc
molecul
repres
sphere
label
p
matur
stage
function
properti
modifi
dc
manipul
incub
either
stimulatori
indic
top
arrow
right
inhibitori
stimuli
indic
bottom
arrow
stimuli
tlr
agonist
antagonist
cytokin
chemokin
chemotherapi
drug
even
achiev
genet
manipul
proinflammatori
dc
dc
orang
present
antigen
peptid
use
treatment
infecti
diseas
cancer
indic
right
text
box
hand
inhibitori
tolerogen
dc
appli
immunosuppress
agent
treatment
disord
transplant
indic
text
box
obvious
largescal
dc
product
quickli
appli
immunotherapi
vaccin
particularli
achiev
strong
antigen
present
requir
stimul
effect
antitumour
immun
respons
immatur
cultur
dc
incub
antigen
phagocytos
process
antigen
peptid
load
onto
mhc
molecul
figur
antigen
also
taa
either
peptid
directli
tumour
lysat
anoth
advantag
ex
vivo
differenti
immatur
dc
genet
modifi
varieti
viral
vector
includ
adenoviru
retroviru
lentiviru
poxviru
even
nonvir
method
mrna
electropor
matur
state
also
control
use
appropri
adjuv
even
molecular
activatorsinhibitor
ideal
immunotherapi
figur
consequ
ex
vivo
gener
dc
use
rais
cell
respons
infecti
agent
cancer
immunotherapi
also
use
toleris
agent
autoimmun
disord
experiment
anim
model
human
therapi
figur
preclin
research
immunotherapi
use
ex
vivo
dc
provid
relev
data
howev
result
alway
translat
expect
clinic
success
human
cancer
immunotherapi
tri
answer
question
research
group
studi
dc
intracellular
signal
pathway
last
year
control
dc
function
comment
administr
foreign
pathogen
antigen
suffici
rais
effect
immun
respons
need
present
cell
context
lead
activ
clonal
expans
achiev
inflamm
driven
sever
stimuli
includ
pathogenderiv
molecul
pathogen
product
bind
receptor
recognis
pathogen
molecular
pattern
tolllik
receptor
tlr
surfac
dc
discuss
dc
matur
present
pathogenderiv
antigen
specif
cell
exactli
strategi
use
adjuv
vaccin
adjuv
tlr
agonist
mediat
inflamm
combin
antigen
interest
boost
antigenspecif
b
cell
respons
classic
adjuv
alum
recent
found
potent
inflammasom
activ
tlr
agonist
wide
use
break
immunolog
toler
toward
autolog
taa
activ
anticanc
immun
respons
tlr
agonist
adjuv
act
induc
dc
matur
reason
instead
classic
adjuv
formul
could
directli
modifi
dc
antigen
present
function
activ
specif
signal
pathway
genet
modif
matur
stimuli
found
adjuv
trigger
correspond
receptor
surfac
dc
intric
network
intracellular
signal
cascad
initi
simplifi
four
key
main
signal
pathway
activ
follow
tlr
cytokin
stimul
nfb
mitogenactiv
protein
kinas
mapk
interferonregulatori
factor
irf
signal
transduc
activ
transcript
stat
pathway
figur
signal
pathway
regul
express
level
mhc
costimulatori
molecul
well
cytokin
product
administr
adjuv
stimul
pathway
also
trigger
neg
feedback
mechan
termin
signal
inhibitori
mechan
ensur
control
excess
inflamm
protect
organ
autoreact
diseas
howev
cancer
immunotherapi
mechan
detriment
break
immunolog
toler
toward
taa
circumv
problem
decid
express
constitut
activ
mutant
intracellular
signal
pathway
purpos
chose
mutant
could
resist
activ
neg
feedback
mechan
mapk
phosphatas
one
key
pathway
regul
immun
inflamm
nfb
transcript
factor
transloc
cell
nucleu
transactiv
wide
array
inflammationrel
gene
constitut
nfb
activ
dc
achiev
overexpress
nfb
induc
kinas
nik
use
adenovir
vector
approach
strongli
potenti
antigen
present
activ
dc
cell
trigger
phenotyp
matur
product
proinflammatori
cytokin
mediat
nikmedi
immunostimulatori
properti
superior
classic
adjuv
howev
strategi
test
use
gfp
model
antigen
anticanc
immunotherapi
similar
strategi
appli
use
lentivir
vector
lentivector
express
kaposi
sarcoma
herpesviru
vflip
protein
vflip
constitut
activ
nfb
pathway
activ
associ
cell
transform
oncogenesi
interestingli
express
dc
use
lentivector
result
phenotyp
matur
product
proinflammatori
cytokin
similarli
nik
overexpress
use
adenovir
vector
case
increas
surviv
achiev
experiment
mhc
iineg
thymoma
model
use
ova
surrog
tumour
antigen
cell
anoth
strategi
achiev
sustain
nfb
activ
interfer
neg
feedback
mechan
recent
ubiquitin
ligas
found
major
neg
regul
nfb
pathway
play
key
regulatori
role
innat
tlr
cytokin
depend
immun
respons
consequ
sirna
silenc
express
dc
prolong
nfb
activ
dc
exhibit
higher
secret
interestingli
strategi
increas
express
potent
immunosuppress
cytokin
therefor
breckpot
col
simultan
silenc
express
turn
increas
antigen
present
capac
human
dc
stimul
expans
cell
tlr
stimul
activ
three
class
mapk
pathway
cjun
ntermin
kinas
jnk
extracellular
signalregul
kinas
erk
mapk
extens
link
proinflammatori
respons
describ
key
driver
dc
phenotyp
function
matur
therefor
test
effect
constitut
activ
lentivector
express
mutant
inactiv
phosphatas
interestingli
sustain
activ
murin
bonemarrowderiv
dc
bmdc
significantli
increas
express
costimulatori
adhes
molecul
icami
surpris
increas
express
even
though
time
experiment
evid
use
inhibitor
contribut
product
howev
recent
evid
challeng
view
contribut
might
indirect
nfb
activ
depend
sourc
dc
direct
vaccin
lentivector
coexpress
mutant
ova
strongli
stimul
expans
ovaspecif
cell
sustain
activ
dc
also
significantli
enhanc
cell
respons
human
transgen
mous
model
mapk
human
dc
could
also
support
ex
vivo
prolifer
cell
consequ
ex
vivo
ovaexpress
dc
use
therapeut
cellular
vaccin
lymphoma
model
interestingli
increas
surviv
observ
although
mice
subsequ
develop
lymphoma
due
immunolog
escap
result
suggest
constitut
activ
strong
enough
yet
even
though
enhanc
antigen
present
properti
modifi
dc
howev
tumour
alway
came
back
even
though
express
strongli
immunogen
xenoantigen
ova
constitut
activ
also
test
dc
genet
modif
use
lentivector
also
link
proinflammatori
respons
regul
dc
surviv
express
fusion
protein
jnk
upstream
kinas
result
constitut
activ
minor
effect
dc
matur
even
clearli
enhanc
cell
prolifer
vaccin
lentivector
encod
ova
nevertheless
strategi
never
test
tumour
model
similarli
express
constitut
activ
mutant
use
lentivector
result
sustain
erk
phosphoryl
erk
activ
murin
bmdc
human
monocytederiv
dc
modc
drove
dc
toward
regulatori
phenotyp
suppress
antigenspecif
cell
expans
expand
antigenspecif
treg
obvious
dc
could
use
suppress
autoimmun
disord
inflammatori
arthriti
could
use
anticanc
immunotherapi
therefor
construct
domin
neg
mutant
replac
activatori
threonin
serin
residu
alanin
activ
loop
aa
express
aa
mutant
dc
inhibit
erk
phosphoryl
drove
dc
phenotyp
matur
strongli
enhanc
cell
antigen
present
properti
even
follow
experi
mapk
reason
erk
inhibit
might
suffici
achiev
effect
anticanc
therapeut
activ
therefor
combin
aa
express
deliveri
target
shrna
murin
dc
use
genet
modifi
dc
cellular
vaccin
lymphoma
model
member
costimulatori
molecul
although
deliv
inhibitori
signal
cell
bind
howev
observ
silenc
antigen
present
dc
interf
ligandinduc
tcr
downmodul
cell
lack
tcr
downmodul
hyperactiv
cell
start
prolifer
much
earlier
acquir
effector
cytotox
activ
shortli
antigen
present
howev
physiolog
condit
cell
exponenti
expand
downmodul
tcr
prevent
untim
attack
critic
mass
cell
reach
therefor
silenc
alon
expand
cell
start
attack
tumour
much
earlier
reach
peak
prolifer
net
result
cancer
cell
underw
immunoedit
earli
reduc
cell
number
favour
select
escap
cell
howev
silenc
combin
erk
inhibitor
dc
cell
could
effect
control
tumour
growth
use
combin
longterm
surviv
observ
lymphoma
mous
model
interestingli
constitut
activ
togeth
silenc
also
achiev
similar
surviv
outcom
follow
strategi
launch
experi
use
endogen
taa
instead
ova
observ
rais
signific
taaspecif
cell
respons
use
silenc
strategi
harder
expect
discuss
mani
discrep
success
observ
experiment
cancer
model
correspond
strategi
human
clinic
practic
discrep
princip
due
activ
potent
immunolog
regulatori
mechan
ensur
immunolog
toler
physiolog
condit
mechan
truli
immunolog
barrier
cancer
immunotherapi
immun
system
capabl
recogn
control
elimin
cancer
cell
certainli
immunogen
howev
two
key
barrier
immun
system
overcom
rais
effect
antitumour
respons
first
one
break
natur
immunolog
toler
toward
selfantigen
stop
activ
taaspecif
cytotox
cell
second
one
tumourinduc
immun
suppress
strongli
inhibit
immunotherapi
treatment
use
clinic
practic
fact
main
factor
contribut
patholog
manifest
cancer
patient
advanc
cancer
possess
immun
system
compromis
unabl
fight
infect
infect
complic
treatment
quickli
lead
death
caus
tumourinduc
immun
suppress
sever
contribut
mechan
mainli
caus
expans
potent
immunosuppress
cell
especi
mention
deserv
regulatori
cell
treg
myeloidderiv
suppressor
cell
mdsc
thu
two
main
goal
cancer
immunotherapi
achiev
strong
activ
circul
autoreact
taaspecif
cell
counteract
activ
treg
mdsc
mention
earlier
review
activ
effector
taaspecif
cell
occur
cancer
shown
contain
class
class
ii
epitop
indic
develop
cell
recognis
peptid
undergo
neg
select
indic
repres
antigen
cell
die
differenti
continu
crossedout
cell
howev
small
percentag
lowaffin
autoreact
cell
surviv
neg
select
green
cell
shown
bottom
figur
howev
cell
strongli
recognis
autoantigen
epitop
also
differenti
highli
suppress
natur
treg
left
figur
treg
releas
thymu
ntreg
control
activ
autoreact
cell
case
get
activ
mistak
antigen
present
possibl
one
major
barrier
cancer
immunotherapi
mani
autoreact
cell
potenti
taaspecif
cytotox
cell
patient
stimul
enhanc
antigen
present
level
dc
howev
neutralis
profound
system
immun
suppress
cancer
patient
heavi
tumour
burden
remain
challeng
immunotherapi
treatment
includ
dc
vaccin
use
strong
adjuv
enhanc
antigen
present
overcom
strongli
immunosuppress
environ
cancer
patient
lie
one
main
factor
discrep
ex
vivo
preclin
data
vivo
human
cancer
immunotherapi
physiolog
condit
million
innocu
organ
compound
direct
contact
organ
includ
bacteria
virus
type
allergen
dust
mite
pollen
manmad
chemic
earlymiddl
centuri
medic
commun
includ
scientist
research
thought
immun
system
constantli
fight
organ
antigen
therefor
immun
system
consid
activ
sentinel
keep
potenti
threat
bay
interpret
immun
turn
accur
seem
immun
system
kept
type
standbi
state
precis
immun
system
activ
suppress
immun
respons
net
result
system
toler
toward
organ
potenti
allergen
would
certainli
highli
detriment
rais
uncontrol
immun
respons
toward
let
us
say
commens
bacteria
gut
truli
danger
threat
aris
immun
system
trigger
mount
immedi
protect
respons
lead
mediumand
longterm
adapt
respons
howev
anoth
puzzl
properti
immun
system
antipathogen
immun
reaction
take
place
autoimmun
reaction
appear
appar
organ
differenti
self
nonself
obvious
critic
question
consid
cancer
immun
cancer
could
consid
self
firstli
system
central
selftoler
start
develop
cell
high
varieti
antigenbind
region
gener
tcr
assembl
also
includ
tcr
recognis
autoantigen
high
medium
low
affin
fortun
highaffin
autoreact
cell
remov
thymu
process
call
clonal
delet
figur
mechan
elimin
autoreact
cell
certainli
help
keep
system
selftoler
howev
clonal
delet
explain
autoimmun
disord
patholog
situat
b
cell
recognis
certain
autolog
antigen
autoreact
cell
attack
selftissu
amplifi
inflamm
lead
develop
diseas
rheumatoid
arthriti
lupu
ankylos
spondyl
therefor
autoreact
cell
fact
escap
clonal
delet
although
physiolog
condit
new
journal
scienc
inact
answer
riddl
mani
highaffin
autoreact
cell
surviv
clonal
delet
differenti
natur
treg
figur
natur
treg
ntreg
larg
contribut
establish
central
toler
cell
intrins
immunosuppress
inhibit
proinflammatori
activ
rang
immun
cell
mani
scientist
might
believ
treg
recent
discov
true
research
treg
biolog
exponenti
increas
rel
recent
howev
treg
new
find
mean
ampl
evid
exist
suppressor
cell
origin
thymu
describ
howev
author
mention
basic
similar
immunostimulatori
helper
counterpart
difficult
separ
even
evid
induc
treg
even
suprisingli
earli
studi
publish
experiment
design
conclus
nearli
ident
recent
paper
treg
exampl
compel
evid
cyclophosphamid
could
break
immunolog
toler
counteract
cell
suppressor
activ
observ
rediscov
year
later
origin
find
even
earli
suppressor
cell
could
correspond
either
treg
mdsc
describ
spleen
tumourbear
mice
recognit
exist
mdsc
separ
immunosuppress
lineag
accumul
larg
number
spleen
tumourbear
mice
less
year
ago
also
suppressor
cell
isol
toleris
mice
author
demonstr
capac
suppress
immun
respons
celltocel
depend
manner
similar
recent
studi
still
clarifi
suppress
celltocel
mechan
exert
treg
much
evid
regard
exist
possibl
research
forgotten
rediscov
around
surpris
larg
bodi
evid
regard
suppressor
cell
time
specif
cell
marker
associ
take
account
monoclon
product
technolog
appear
use
phenotyp
immun
cell
regul
therefor
phenotyp
characteris
treg
late
simpli
occur
fact
made
difficult
isol
studi
manipul
earli
sakaguchi
colleagu
associ
high
express
level
cell
natur
treg
activ
highaffin
chain
directli
associ
treg
suppressor
activ
sequestr
requir
cell
surviv
clonal
expans
addit
signal
requir
treg
homeostasi
major
breakthrough
took
place
transcript
factor
shown
requir
treg
develop
marker
transcript
factor
associ
treg
far
remain
reliabl
particularli
mice
strong
associ
high
level
express
regulatori
cell
strongli
relaunch
research
treg
nevertheless
ntreg
clonal
delet
explain
acquir
toler
toward
autoantigen
express
thymu
without
mention
plethora
foreign
antigen
constantli
come
contact
theoret
speak
immun
respons
constantli
place
toward
antigen
although
mean
case
organ
remain
toler
toward
antigen
whether
autoantigen
foreignxenoantigen
interestingli
describ
treg
marker
anoth
set
treg
origin
directli
thymu
discov
treg
also
coexpress
differenti
peripheri
antigenexperienc
nonregulatori
cell
induc
treg
also
call
cell
differenti
antigen
present
tolerogen
dc
absenc
inflamm
neg
costimul
tgfexpress
mediat
induc
treg
differenti
antigen
present
anoth
set
induc
lack
express
cell
also
differenti
antigen
present
presenc
potent
immunosuppress
cytokin
known
also
play
key
role
maintain
peripher
mucos
toler
treg
major
player
keep
system
immunolog
toler
unfortun
cancer
immunotherapi
natur
treg
recognis
autoantigen
differenti
thymu
even
though
autoreact
cell
escap
activ
control
ntreg
target
autoantigen
elimin
treg
use
antibodi
result
tumour
regress
demonstr
direct
link
inhibitori
activ
treg
lack
antitumour
immun
respons
fact
use
system
b
cell
lymphoma
model
express
flu
haemagglutinin
surrog
tumour
antigen
zhou
col
demonstr
tumour
induc
antigenspecif
treg
even
vaccin
effector
antitumour
cell
antigenspecif
treg
expand
treg
could
control
antitumour
cytotox
cell
key
observ
demonstr
tumour
expand
treg
escap
cell
attack
increas
number
circul
tumourinfiltr
treg
also
observ
cancer
patient
therefor
even
though
tumour
certainli
immunogen
taaspecif
cell
end
render
inact
treg
activ
thu
treg
strongli
influenc
equilibrium
tumour
growth
antitumour
immun
respons
toward
cancer
growth
immun
escap
evid
tumour
caus
treg
differenti
convert
myeloid
dc
tolerogen
dc
addit
tumour
cell
produc
rang
cytokin
metabol
enzym
stimul
convers
treg
also
promot
mdsc
differenti
cyclooxygenas
prostaglandin
interestingli
mdsc
infiltr
tumour
recruit
treg
chemokin
secret
manner
therefor
concert
action
mdsc
treg
stimul
tumour
progress
tumour
also
produc
key
cytokin
growth
factor
convert
treg
situ
drain
lymph
node
prototyp
tgfand
treg
inhibit
immun
respons
wide
rang
mechan
infecti
toler
aminoacid
consumpt
express
potent
immunosuppress
cytokin
tgfand
deliveri
neg
signal
antigen
present
cell
particularli
import
last
point
usual
mediat
express
surfac
treg
even
though
treg
extens
studi
specif
mechan
inhibit
immun
respons
still
remain
sort
mysteri
firstli
exhibit
higher
affin
propos
compet
bind
complet
would
respons
inhibit
apc
antigen
present
function
could
possibl
bind
would
deliv
neg
signal
cell
apc
interestingli
strong
evid
treg
physic
remov
molecul
surfac
antigen
present
cell
transendocytosi
complex
would
degrad
leav
apc
without
costimulatori
molecul
result
would
apc
highli
reduc
antigen
present
capac
immunotherapi
therapeut
elimin
treg
inhibit
function
major
goal
cancer
immunotherapi
improv
therapeut
activ
discuss
treg
express
surfac
marker
make
suscept
antibodytarget
strategi
combin
block
antibodi
antibodi
melanoma
model
result
effect
immunotherapi
elimin
treg
enhanc
immun
respons
endogen
taa
likewis
simultan
blockad
signal
also
strongli
inhibit
treg
function
preclin
clinic
data
system
administr
antibodi
clearli
show
target
immunosuppress
cell
pathway
effect
therapeut
procedur
humanis
approv
antibodi
ipilimumab
clearli
boost
antitumour
activ
human
therapi
significantli
prolong
surviv
melanoma
nonsmal
cell
lung
carcinoma
patient
interestingli
demonstr
activ
block
antibodi
fact
depend
specif
treg
deplet
within
tumour
system
instead
block
activ
treg
cell
seem
antibodi
physic
remov
treg
via
macrophag
howev
might
effect
less
immunogen
cancer
someth
taken
account
antibodybas
immunostimulatori
strategi
exhibit
import
inflammatori
cytotox
nevertheless
like
better
outcom
expect
combin
therapi
dc
immunostimulatori
treatment
make
resist
treg
suppress
activ
genet
modif
dc
use
mrna
electropor
express
constitut
activ
ligand
togeth
confer
treg
resist
cell
inhibit
suppress
activ
toward
effector
cell
likewis
constitut
inhibit
erk
phosphoryl
express
domin
neg
mutant
tgfsilenc
antigen
present
dc
also
strongli
inhibit
vivo
expans
induc
treg
consequ
erk
inhibit
synergist
enhanc
antitumour
properti
silenc
dc
recent
commonli
use
chemotherapeut
agent
cyclophosphamid
fluorouracil
oxaliplatin
shown
inhibit
develop
treg
ex
vivo
vivo
effect
contribut
antitumour
capac
stimul
anticanc
immun
respons
fact
evid
broad
spectrum
kinas
inhibitor
frequent
use
chemotherapi
potent
immunostimulatori
capac
sunitinib
without
like
direct
action
cancer
cell
would
suffici
full
efficaci
inhibit
tyrosin
kinas
mapk
erk
could
strong
immunostimulatori
activ
stimul
dc
matur
simultan
inhibit
expans
treg
mdsc
treg
certainli
import
immunosuppress
cell
enhanc
cancer
progress
central
role
anoth
suppress
cell
type
come
light
recent
year
myeloidderiv
suppressor
cell
mdsc
mdsc
includ
heterogen
myeloid
cell
popul
common
phenotyp
function
characterist
expand
highli
inflammatori
environ
infect
transplant
cancer
mice
express
high
level
granulocytespecif
marker
compris
two
surfac
marker
name
basi
rel
express
mdsc
classifi
monocyt
high
neglow
granulocyt
high
high
murin
popul
also
correspond
counterpart
human
recent
year
mdsc
recognis
cell
type
larg
respons
tumourinduc
immun
suppress
caus
inefficaci
immunotherapeut
procedur
clinic
practic
cell
suddenli
becom
target
interest
research
medic
pharmaceut
compani
cancer
patient
heavi
tumour
burden
tumour
produc
cytokin
molecul
direct
myeloid
differenti
toward
mdsc
instead
monocyt
dc
macrophag
inflammatori
granulocyt
mdsc
system
distribut
infiltr
tumour
inhibit
antitumour
cell
respons
antigenspecif
unspecif
mechan
new
journal
scienc
spread
cancer
cell
primari
tumour
key
patholog
featur
cancer
howev
system
immunosuppress
hamper
immun
system
elimin
cancer
cell
exist
myeloid
cell
contribut
cancer
progress
known
sever
year
howev
recent
mdsc
recognis
specialis
lineag
immunosuppress
cell
strongli
expand
cancer
although
recognit
mdsc
specif
cell
lineag
controversi
experiment
evid
strongli
support
exist
role
tumourexpand
mdsc
possess
strong
cell
inhibitori
activ
antigenspecif
nonspecif
mechan
antigenspecif
suppress
mechan
may
includ
induct
treg
due
antigen
present
presenc
immunosuppress
cytokin
induct
cell
anergi
cell
anergi
encompass
twostep
process
firstli
cell
undergo
antigen
present
absenc
signific
posit
costimul
might
case
mdsc
highli
immatur
myeloid
cell
cell
expand
limit
effector
activ
second
antigen
encount
antigen
recognit
target
cell
cell
becom
unreact
anerg
antigen
nonspecif
mechan
includ
aminoacid
deplet
upregul
aminoacidconsum
enzym
ino
express
would
also
contribut
arginin
deplet
also
product
immunosuppress
cytokin
tgfbi
mdsc
overli
inhibit
activ
immun
cell
therapeut
target
mdsc
differenti
vivo
activ
rang
cytokin
cancer
cell
product
inflammatori
environ
also
strongli
contribut
differenti
acquisit
suppress
activ
granulocyt
monocyt
coloni
stimul
factor
gmcsf
produc
cancer
cell
strongli
contribut
mdsc
differenti
would
explain
use
gmcsf
human
cancer
immunotherapi
mix
respons
proinflammatori
environ
driven
either
cytokin
tlr
ligand
seem
strongli
contribut
differenti
combin
gmcsf
agonist
lipopolysaccharid
lp
drive
differenti
bone
marrow
myeloid
precursor
mdsclike
cell
bmderiv
mdsc
strongli
inhibit
cell
respons
celltocel
contact
mechan
ino
express
respect
cancer
cell
produc
rang
cytokin
differenti
mdsc
also
provid
strong
immunosuppress
capac
combin
gmcsf
proinflammatori
cytokin
strongli
potenti
suppress
activ
rang
cytokin
produc
primari
tumour
cancer
cell
line
also
contribut
mdsc
differenti
although
minor
extent
presenc
combin
gmcsf
mcsf
also
result
particularli
suppress
mdsc
cell
could
inhibit
experiment
graftversushost
diseas
express
arginas
observ
pose
critic
problem
cancer
immunotherapi
possibl
therapeut
target
mdsc
differenti
proinflammatori
type
respons
usual
thought
benefici
activ
anticanc
cytotox
cell
might
true
extent
howev
proinflammatori
environ
favour
mdsc
activ
physiolog
condit
regul
excess
inflamm
lie
major
problem
adequ
design
cancer
immunotherapi
protocol
rais
respons
without
significantli
expand
mdsc
treg
apart
myeloiddifferenti
proinflammatori
cytokin
prostaglandin
tgfcan
effect
drive
mdsc
differenti
found
abund
tumourderiv
exosom
combin
gmcsf
lp
differenti
human
mdsc
posit
loop
involv
induct
mdsc
tougher
therapeut
target
comparison
treg
deplet
antibodi
gener
term
myeloidspecif
blockingdeplet
molecul
possibl
elimin
proinflammatori
myeloid
cell
cell
play
critic
role
taa
antigen
present
discuss
chemotherapi
drug
metabol
compound
inhibit
expans
mdsc
treg
possibl
inhibit
signal
gener
term
inhibitori
mdsc
cell
reli
activ
suppress
activ
fact
genet
modif
myeloid
cell
use
silenc
shrna
deliv
lentivector
vaccin
also
highli
like
broad
spectrum
kinas
inhibitor
alreadi
use
human
oncolog
might
shift
balanc
toward
proinflammatori
dc
differenti
howev
scientif
point
view
preclin
studi
could
mdsc
counteract
drug
identifi
without
take
clinic
trial
current
mdsc
isol
directli
spleen
tumour
tumourbear
mice
render
rel
low
number
cell
yield
insuffici
larg
screen
candid
drug
isol
mdsc
fail
prolifer
ex
vivo
surviv
sever
compromis
hamper
studi
therapeut
applic
even
though
differenti
ex
vivo
bone
marrow
mononuclear
cell
mdsc
yield
rang
best
case
addit
mani
differ
protocol
possibl
result
heterogen
nonrepres
mdsc
popul
anoth
key
point
take
account
mdsc
subtli
differ
depend
cancer
background
differenti
mean
type
cancer
larg
number
mdsc
reproduc
obtain
larg
scale
high
throughput
drug
test
meantim
small
scale
studi
mice
limit
human
sampl
perform
studi
effect
antineoplast
treatment
mdsc
differenti
function
cancer
immunotherapi
nich
oncolog
accord
opinion
tumour
certainli
immunogen
taaspecif
cell
fact
expand
infiltr
tumour
even
infrequ
case
spontan
tumour
regress
howev
key
point
cancer
immunotherapi
develop
strong
taaspecif
cell
respons
qualiti
quantiti
prevent
immunolog
escap
result
tumour
immun
edit
one
way
achiev
potenti
antigen
present
begin
manipul
potent
antigen
present
cell
dc
mani
biomed
research
group
includ
use
murin
human
ex
vivo
differenti
dc
develop
anticanc
vaccin
dc
manipul
process
present
taa
antigen
peptid
mhc
use
antigen
present
assay
cell
evalu
therapeut
potenti
rang
antineoplast
treatment
ex
vivo
antigen
present
system
vivo
tumour
anim
model
certainli
provid
invalu
inform
evalu
novel
anticanc
immunotherapi
treatment
howev
major
inconsist
result
preclin
drug
test
clinic
trial
human
patient
reason
discrep
human
cancer
patient
suffer
diseas
time
time
go
physician
tumour
like
exert
immunosuppress
activ
therefor
question
counteract
immunosuppress
cell
organ
treg
deplet
inhibit
differenti
becom
realiti
even
though
tregdeplet
treatment
highli
toxic
howev
new
cancer
immunotherapi
agent
aim
counteract
activ
mdsc
strong
correl
success
convent
antineoplast
treatment
inhibit
mdsc
treg
expans
howev
nowaday
yet
possibl
faith
effici
replic
cancerdriven
mdsc
differenti
ex
vivo
reproduc
effici
mdsc
differenti
system
could
set
ex
vivo
similar
dc
product
protocol
antineoplas
treatment
could
firstli
assess
preclin
assay
immortalis
mdsc
cell
line
could
use
substitut
primari
mdsc
howev
cell
line
obtain
retroviru
transduct
express
oncogen
vmyc
vraf
highli
like
alter
behaviour
toward
antineoplast
treatment
conclus
tumour
immunogen
previous
thought
howev
concert
action
sever
immunosuppress
cell
keep
immun
system
bay
research
look
system
test
anticanc
treatment
treg
mdsc
function
ex
vivo
treg
elimin
use
deplet
antibodi
mdsc
difficult
target
ex
vivo
mdsct
cell
antigen
present
assay
conserv
mdsc
prolif
capac
replic
behaviour
found
within
tumour
ex
vivo
strategi
uncov
novel
antineoplast
drug
preclin
assay
save
preciou
econom
human
resourc
requir
human
clinic
trial
author
declar
conflict
interest
